Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8101MR)

This product GTTS-WQ8101MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8101MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14600MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ8496MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ15078MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SSS-23
GTTS-WQ2850MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG-570
GTTS-WQ12565MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NV-02
GTTS-WQ11575MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MG-A271
GTTS-WQ11263MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI4736
GTTS-WQ8442MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HspE7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW